Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHSCT for MNGIE
NCT02427178Phase 1Withdrawn
- Start
- Mar 2015
- Primary completion
- Jun 2022
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of allogeneic hematopoietic stem cells in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Primary endpoint: neutrophil count at 42 days. Planned start Mar 2015; status: withdrawn.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
Beyond the preview
Go deeper on NCT02427178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02427178.